Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress - PubMed (original) (raw)
doi: 10.1016/j.jpain.2015.04.007. Epub 2015 May 7.
Daisy Zamora 2, Alexandros Makriyannis 3, JodiAnne T Wood 3, J Douglas Mann 4, Keturah R Faurot 2, Beth A MacIntosh 5, Sharon F Majchrzak-Hong 6, Jacklyn R Gross 7, Amber B Courville 8, John M Davis 9, Joseph R Hibbeln 6
Affiliations
- PMID: 25958314
- PMCID: PMC4522350
- DOI: 10.1016/j.jpain.2015.04.007
Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress
Christopher E Ramsden et al. J Pain. 2015 Aug.
Abstract
Omega-3 and omega-6 fatty acids are biosynthetic precursors of endocannabinoids with antinociceptive, anxiolytic, and neurogenic properties. We recently reported that targeted dietary manipulation-increasing omega-3 fatty acids while reducing omega-6 linoleic acid (the H3-L6 intervention)-reduced headache pain and psychological distress among chronic headache patients. It is not yet known whether these clinical improvements were due to changes in endocannabinoids and related mediators derived from omega-3 and omega-6 fatty acids. We therefore used data from this trial (N = 55) to investigate 1) whether the H3-L6 intervention altered omega-3- and omega-6-derived endocannabinoids in plasma and 2) whether diet-induced changes in these bioactive lipids were associated with clinical improvements. The H3-L6 intervention significantly increased the omega-3 docosahexaenoic acid derivatives 2-docosahexaenoylglycerol (+65%, P < .001) and docosahexaenoylethanolamine (+99%, P < .001) and reduced the omega-6 arachidonic acid derivative 2-arachidonoylglycerol (-25%, P = .001). Diet-induced changes in these endocannabinoid derivatives of omega-3 docosahexaenoic acid, but not omega-6 arachidonic acid, correlated with reductions in physical pain and psychological distress. These findings demonstrate that targeted dietary manipulation can alter endocannabinoids derived from omega-3 and omega-6 fatty acids in humans and suggest that 2-docosahexaenoylglycerol and docosahexaenoylethanolamine could have physical and/or psychological pain modulating properties.
Trial registration: ClinicalTrials.gov (NCT01157208) PERSPECTIVE: This article demonstrates that targeted dietary manipulation can alter endocannabinoids derived from omega-3 and omega-6 fatty acids and that these changes are related to reductions in headache pain and psychological distress. These findings suggest that dietary interventions could provide an effective, complementary approach for managing chronic pain and related conditions.
Keywords: 2-arachidonoylglycerol; 2-docosahexaenoylglycerol; Endocannabinoids; docosahexaenoylethanolamine; headache; psychological distress.
Published by Elsevier Inc.
Conflict of interest statement
Conflicts of Interest: The authors declare no conflicts of interest.
Figures
Figure 1. Model depicting diet-induced alterations in n-3 and n-6 derived endocannabinoids
(A) Dietary n-3 and n-6 polyunsaturated fatty acids compete for enzymatic conversion into their respective elongated and desaturated products, notably n-3 DHA and n-6 AA. (B) n-3 DHA and EPA and n-6 AA and LA compete for esterification into cell membranes. (C) Membrane n-3 DHA and n-6 AA are converted to their respective glycerol-ester and N-acylethanolamine endocannabinoids in proportion to available substrate. (D) n-3 and n-6 fatty acids can be converted to numerous other lipid autacoids with pro- or anti-nociceptive properties (eg, prostaglandins, EETs, HODEs, lipoxins, resolvins, protectins). DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; AA, arachidonic acid; DHG, docosahexaenoylglycerol; DHA-EA, docosahexaenoylethanolamine; AG, arachidonoylglycerol; AEA, arachidonoylethanolamine; EET, epoxyeicosatrienoic acid; HODE, hydroxyoctadecadienoic acid; CB, cannabinoid; TRPV1, transient receptor potential cation channel, subfamily V, member 1.
Figure 2. Precursor fatty acids and their n-3 and n-6 endocannabinoid products in plasma after 12 weeks
Plots are post-estimations of linear regression models for the effect plasma fatty acids on each endocannabinoid after 12 weeks on the Chronic Daily Headache Study (n=55), adjusting for the baseline value of each respective endocannabinoid and fatty acid. Endocannabinoids are measured in ng/mL. The shaded areas around regression lines are 95% confidence intervals. DHG, docosahexaenoylglycerol; DHA-EA, docosahexaenoylethanolamine; 2-AG, 2-arachidonoylglycerol; AEA, arachidonoylethanolamine; DHA, docosahexaenoic acid; n-6, omega-6; HUFA, highly unsaturated fatty acids.
Similar articles
- Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial.
Ramsden CE, Faurot KR, Zamora D, Palsson OS, MacIntosh BA, Gaylord S, Taha AY, Rapoport SI, Hibbeln JR, Davis JM, Mann JD. Ramsden CE, et al. Pain. 2015 Apr;156(4):587-596. doi: 10.1097/01.j.pain.0000460348.84965.47. Pain. 2015. PMID: 25790451 Free PMC article. Clinical Trial. - Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial.
Ramsden CE, Zamora D, Faurot KR, MacIntosh B, Horowitz M, Keyes GS, Yuan ZX, Miller V, Lynch C, Honvoh G, Park J, Levy R, Domenichiello AF, Johnston A, Majchrzak-Hong S, Hibbeln JR, Barrow DA, Loewke J, Davis JM, Mannes A, Palsson OS, Suchindran CM, Gaylord SA, Mann JD. Ramsden CE, et al. BMJ. 2021 Jun 30;374:n1448. doi: 10.1136/bmj.n1448. BMJ. 2021. PMID: 34526307 Free PMC article. Clinical Trial. - Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial.
Ramsden CE, Faurot KR, Zamora D, Suchindran CM, MacIntosh BA, Gaylord S, Ringel A, Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, Palsson O, Barrow DA, Mann DJ. Ramsden CE, et al. Pain. 2013 Nov;154(11):2441-2451. doi: 10.1016/j.pain.2013.07.028. Epub 2013 Jul 22. Pain. 2013. PMID: 23886520 Free PMC article. Clinical Trial. - Interplay Between n-3 and n-6 Long-Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair.
Dyall SC. Dyall SC. Lipids. 2017 Nov;52(11):885-900. doi: 10.1007/s11745-017-4292-8. Epub 2017 Sep 5. Lipids. 2017. PMID: 28875399 Free PMC article. Review. - ω-3 and ω-6 Polyunsaturated Fatty Acids, Obesity and Cancer.
D'Angelo S, Motti ML, Meccariello R. D'Angelo S, et al. Nutrients. 2020 Sep 10;12(9):2751. doi: 10.3390/nu12092751. Nutrients. 2020. PMID: 32927614 Free PMC article. Review.
Cited by
- Transmission of risk from parents with chronic pain to offspring: an integrative conceptual model.
Stone AL, Wilson AC. Stone AL, et al. Pain. 2016 Dec;157(12):2628-2639. doi: 10.1097/j.pain.0000000000000637. Pain. 2016. PMID: 27380502 Free PMC article. Review. - Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model.
Lamontagne-Proulx J, Coulombe K, Dahhani F, Côté M, Guyaz C, Tremblay C, Di Marzo V, Flamand N, Calon F, Soulet D. Lamontagne-Proulx J, et al. Nutrients. 2021 Nov 24;13(12):4218. doi: 10.3390/nu13124218. Nutrients. 2021. PMID: 34959768 Free PMC article. - Perspective: Moving Toward Desirable Linoleic Acid Content in Infant Formula.
Carlson SE, Schipper L, Brenna JT, Agostoni C, Calder PC, Forsyth S, Legrand P, Abrahamse-Berkeveld M, van de Heijning BJM, van der Beek EM, Koletzko BV, Muhlhausler B. Carlson SE, et al. Adv Nutr. 2021 Dec 1;12(6):2085-2098. doi: 10.1093/advances/nmab076. Adv Nutr. 2021. PMID: 34265035 Free PMC article. Review. - A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.
Ramsden CE, Domenichiello AF, Yuan ZX, Sapio MR, Keyes GS, Mishra SK, Gross JR, Majchrzak-Hong S, Zamora D, Horowitz MS, Davis JM, Sorokin AV, Dey A, LaPaglia DM, Wheeler JJ, Vasko MR, Mehta NN, Mannes AJ, Iadarola MJ. Ramsden CE, et al. Sci Signal. 2017 Aug 22;10(493):eaal5241. doi: 10.1126/scisignal.aal5241. Sci Signal. 2017. PMID: 28831021 Free PMC article.
References
- Almeida-Santos AF, Gobira PH, Rosa LC, Guimaraes FS, Moreira FA, Aguiar DC. Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray. Behavioural brain research. 2013;252:10–17. - PubMed
- Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. Cephalalgia: an international journal of headache. 2012;32:822–833. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- Z99 AA999999/ImNIH/Intramural NIH HHS/United States
- T32 AT003378/AT/NCCIH NIH HHS/United States
- UL1 TR002489/TR/NCATS NIH HHS/United States
- R01 DA007215/DA/NIDA NIH HHS/United States
- T32-AT003378/AT/NCCIH NIH HHS/United States
- P01 DA009158/DA/NIDA NIH HHS/United States
- DK056350/DK/NIDDK NIH HHS/United States
- DA09158/DA/NIDA NIH HHS/United States
- UL1 TR001111/TR/NCATS NIH HHS/United States
- DA07215/DA/NIDA NIH HHS/United States
- UL1RR025747/RR/NCRR NIH HHS/United States
- P30 DK056350/DK/NIDDK NIH HHS/United States
- UL1 RR025747/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical